Profund Advisors LLC lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 15.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 24,084 shares of the company’s stock after selling 4,525 shares during the quarter. Profund Advisors LLC’s holdings in CRISPR Therapeutics were worth $1,352,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Geneos Wealth Management Inc. raised its holdings in shares of CRISPR Therapeutics by 172.3% in the 2nd quarter. Geneos Wealth Management Inc. now owns 561 shares of the company’s stock worth $31,000 after purchasing an additional 355 shares during the period. Pinnacle Holdings LLC bought a new stake in shares of CRISPR Therapeutics in the 1st quarter worth approximately $48,000. Spire Wealth Management raised its holdings in shares of CRISPR Therapeutics by 101.8% in the 2nd quarter. Spire Wealth Management now owns 793 shares of the company’s stock worth $45,000 after purchasing an additional 400 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of CRISPR Therapeutics by 1,726.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 968 shares of the company’s stock worth $54,000 after purchasing an additional 915 shares during the period. Finally, Nkcfo LLC purchased a new position in CRISPR Therapeutics in the 2nd quarter valued at approximately $60,000. Institutional investors own 68.20% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on CRSP. Royal Bank of Canada reduced their price objective on shares of CRISPR Therapeutics from $55.00 to $50.00 and set a “sector perform” rating for the company in a research note on Tuesday, November 7th. Needham & Company LLC reduced their price objective on shares of CRISPR Therapeutics from $88.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, November 7th. Mizuho began coverage on shares of CRISPR Therapeutics in a research note on Tuesday, September 26th. They issued a “buy” rating and a $82.00 price objective for the company. Citigroup upgraded shares of CRISPR Therapeutics from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research note on Thursday, August 17th. Finally, Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $123.00 to $110.00 and set a “buy” rating for the company in a research note on Monday, August 7th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $69.88.
CRISPR Therapeutics Stock Performance
Shares of NASDAQ:CRSP opened at $72.18 on Tuesday. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $76.19. The firm has a fifty day moving average of $47.07 and a 200 day moving average of $53.29. The firm has a market capitalization of $5.73 billion, a PE ratio of -16.15 and a beta of 1.57.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its earnings results on Monday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.04) by $0.63. CRISPR Therapeutics had a negative net margin of 240.84% and a negative return on equity of 19.10%. During the same period last year, the firm earned ($2.24) earnings per share. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -3.59 EPS for the current fiscal year.
CRISPR Therapeutics Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Five stocks we like better than CRISPR Therapeutics
- ESG Stocks, What Investors Should Know
- Safeguard your portfolio with these three bargain stocks
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Membership clubs gain leverage for the consumer rebound
- How to Evaluate a Stock Before Buying
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.